Success Story: NIW + EB1A Approved! A Chinese Doctor Overcomes EB1A RFE with Premium Processing Speed
Client’s Testimonial:
“This was the most important day of my life. Thank you so much for your professional service.”
On July 24th, 2024, and June 7th, 2025, we received another I-140 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) Approvals for a Doctor in the Field of Hepatology (Approval Notice).
General Field: Hepatology
Position at the Time of Case Filing: Doctor
Country of Origin: China
Country of Residence at the Time of Filing: China
Approval Notice Date: : July 24th, 2024 (NIW); June 7th, 2025 (EB1A)
Processing Time: 1 month, 19 days (NIW); 3 months, 4 days (EB1A) (Premium Processing Requested)
Case Summary:
We are proud to share the approval of both the National Interest Waiver (NIW) and EB1A petitions for a highly accomplished researcher in hepatology. The NIW petition was approved in July 2024, and the EB1A petition was approved in June 2025 following premium processing and a successful response to a Request for Evidence (RFE). These approvals reflect the petitioner’s significant contributions to improving treatment strategies for liver failure and liver regeneration.
Driving Innovation in Liver Injury and Regenerative Medicine
With a Ph.D. in medical science, the petitioner has established himself as a recognized expert in the fields of liver injury, liver regeneration, and precision therapeutics. His research focuses on the treatment of both acute and chronic liver failure, leveraging novel approaches such as mRNA nanoparticles for targeted drug delivery and macrophage-targeted therapies to mitigate ischemia-reperfusion injury.
Strong Research Record and Growing Influence
At the time of filing, the petitioner had authored:
- 16 peer-reviewed journal articles, including 4 first-authored and 2 corresponding-authored papers.
These publications had received 388 citations, reflecting widespread recognition of his work within the biomedical and liver research communities. His articles have influenced numerous independent studies focused on liver inflammation, therapeutic development, and immune system modulation.
He has also served as a peer reviewer for at least 42 journals, confirming his stature as a trusted authority in hepatology and liver-targeted therapies.
National Recognition and Funding Support
The petitioner’s research has been funded by prestigious institutions, including the National Key Research and Development Program of China and the National Natural Science Foundation of China (NSFC). These funding sources demonstrate the national and global value placed on his research.
Expert Endorsements Strengthen the Case
The EB1A petition was supported by four letters of recommendation from well-established experts in liver research and biomedical science. These letters highlighted the originality, applicability, and clinical importance of his work.
“His record of success in research, along with his services as a judge for the work of his peers, clearly showcases the immense value and indispensability that his research holds within his field of study.”
Advancing U.S. Health Outcomes through Targeted Liver Therapies
The petitioner’s research directly addresses a growing national and global health burden. By developing more effective therapies for liver failure and leveraging cutting-edge drug delivery platforms, his work aligns closely with U.S. healthcare innovation goals.
We are honored to have supported this exceptional researcher in achieving both NIW and EB1A approvals and look forward to his continued contributions to liver medicine and translational biomedical research.